**PATENT** 

# N THE UNITED STATES PATENT AND TRADEMARK OFFICE (MBHB Case No. 01-1693-N)

In re Application of:	)	
Fang et al.	)	
Serial No.: 09/896,874	)	Group Art Unit: 1621
Filed: June 29, 2001	)	Examiner: Shailendra Kumar
For: Compounds to Treat Alzheimer's Disease	)	

# SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Supplemental Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the references cited below are enclosed. These references are also listed on the enclosed Supplemental PTO Form 1449.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative relevance between references, whether cited in this or prior statements. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

### **United States Patents**

1. Gordon et al., U.S. Patent No. 4,474,778, issued October 2, 1984.

1

2. Weller III et al. U.S. Patent No. 4,512,988, issued April 23, 1985.

06/17/2004 JADDO1 00000072 09896874

02 FC:1252

420.00 OP

3. Abbenate et al., U.S. Patent No. 6,043,357, issued March 28, 2000.

# **Other Documents**

4. Flynn et al., J. Am. Chem. Soc. (1997) 119:4874-4881.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Suplemental Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

Respectfully submitted,

Dated: June 15, 2004

By:

Bradley W. Crawford

Reg. No. 50,494

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
			09/896,874
SUPPLEMENTAL INFOR STATEMENT E Use several she			
70, 40	Applicant:		
JUN 1 5 2004 (S)	Fang, et al.		
TRADEMARKS		Filing Date:	Group:
WADE!		June 29, 2001	1621

#### **U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	1.	4,474,778	Oct 2, 1984	Gordon et al.			
	2.	4,512,988	April 23, 1985	Weller III et al.			
	3.	6,043,357	March 28, 2000	Abbenate et al.			

## **FOREIGN PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Country	Class	Subclass	Tran Yes	slation No

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	4.	Flynn et al., J. Am. Chem. Soc. (1997) 119:4874-4881.		
EXAMINER			DATE CONSIDERED	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.